95%Confidence
0Views
FDASource
2026-04-18Date
Summary
K.C. Pharmaceuticals' sterility issues now include redness relief eye drops, confirming facility-wide contamination problems. The industrial and pharmaceutical distribution channels indicate both consumer and workplace safety concerns.
Actionable: Implement emergency quality control measures for all sterile ophthalmic products and seek immediate regulatory guidance.
AI Confidence: 95%
Data Points
firmK.C. Pharmaceuticals, Inc
classificationClass II
statusOngoing
distributionNationwide in the US
productSterile EYE DROPS REDNESS LUBRICANT (glycerin 0.25% and naphazoline HCl 0.012%), 0.5 fl oz (15 mL) bottles; a) Industrial Eye Relief, Distributed by:
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now